Evidence map›Paper›PMID 38911274›Full record

ArticleTransplantation direct2024

Evaluating Islet Cell Isolation and Transplantation From Donors Following Medical Assistance in Dying.

Alessandro Parente, Kevin Verhoeff, Tatsuya Kin, Joshua Hefler, Braulio A Marfil-Garza, Norberto Sanchez-Fernandez, Anna Lam, James Lyon, Doug O'Gorman, Khaled Z Dajani and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Transplantation direct, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Alessandro ParenteClinical Islet Transplant Program, University of Alberta, Edmonton, AB, Canada.ORCID https://orcid.org/0000-0001-5506-224X
Kevin VerhoeffClinical Islet Transplant Program, University of Alberta, Edmonton, AB, Canada.
Tatsuya KinClinical Islet Transplant Program, University of Alberta, Edmonton, AB, Canada.
Joshua HeflerClinical Islet Transplant Program, University of Alberta, Edmonton, AB, Canada.
Braulio A Marfil-GarzaAlberta Diabetes Institute, University of Alberta, Edmonton, AB, Canada.
Norberto Sanchez-FernandezClinical Islet Transplant Program, University of Alberta, Edmonton, AB, Canada.
Anna LamClinical Islet Transplant Program, University of Alberta, Edmonton, AB, Canada.
James LyonAlberta Diabetes Institute, University of Alberta, Edmonton, AB, Canada.
Doug O'GormanClinical Islet Transplant Program, University of Alberta, Edmonton, AB, Canada.
Khaled Z DajaniClinical Islet Transplant Program, University of Alberta, Edmonton, AB, Canada.
Blaire L AndersonClinical Islet Transplant Program, University of Alberta, Edmonton, AB, Canada.
David L BigamClinical Islet Transplant Program, University of Alberta, Edmonton, AB, Canada.
Patrick E MacDonaldAlberta Diabetes Institute, University of Alberta, Edmonton, AB, Canada.
A M James ShapiroClinical Islet Transplant Program, University of Alberta, Edmonton, AB, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Limited information is available regarding outcomes of islet cell isolation (ICI) and transplantation (ITx) using medical assistance in dying (MAiD) donors. We aimed to assess the feasibility and outcomes of ICI and ITx in MAiD donors. Methods: ICI and ITx from MAiD were compared with donation after circulatory death (DCD) type III between 2016 and 2023. Differences of isolated islet equivalents (IEQs), numeric viability and other quantitative in vitro metabolic measures were assessed. Results: Overall, 81 ICIs were available of whom 34 (42%) and 47 (58%) from MAiD and DCD-III, respectively. There were no differences of pancreas and digested tissue weight and islets viability among the 2 groups; however, cold ischemic time was longer in MAiD (11.5 versus 9.1 h; Conclusions: ICI from MAiD donor pancreas may be successfully transplanted with comparable outcomes to DCD-III and may be used for research. These results justify additional efforts to consider MAiD as another valuable source of grafts for ITx. Further multicenter studies and larger clinical experience are needed to validate our findings.

Identifiers

PMID38911274
PMCPMC11191926

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.